An Open, Multicenter Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Bial; Roxall Medizin GmbH
- 28 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 28 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
- 09 Sep 2016 New trial record